ABOS - Halozyme Acumen enter collaboration for Alzheimer's drug candidate
2023-11-06 08:23:39 ET
More on Acumen Pharmaceuticals, Halozyme Therapeutics, etc.
- Navigating Acumen's Alzheimer's Risk And Reward
- Acumen Pharmaceuticals: Novel Alzheimer's Molecule With Positive Early Data
- Halozyme: Intriguing Buy Prospect Despite This Week's PDUFA Setback
- Halozyme Therapeutics Q3 2023 Earnings Preview
- Bristol Myers succeeds in Phase 3 trial for subcutaneous Opdivo
For further details see:
Halozyme, Acumen enter collaboration for Alzheimer's drug candidate